MedTrace Logo

Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

NCT00105157 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2015-12-04

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.

Conditions

  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Interventions

DRUG

Comparator: MK0518

MK0518 oral tablets 200 mg b.i.d, for 24 weeks

DRUG

MK0518

MK0518 oral tablets 400 mg b.i.d, for 24 weeks

DRUG

MK0518

MK0518 oral tablets 600 mg b.i.d, for 24 weeks

DRUG

Placebo

Placebo to MK0518, oral tablet b.i.d, for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-10-31
Completion
2009-07-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105157 on ClinicalTrials.gov